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dicting a response to parenteral iron administration, but it stillDiagnostic value of iron indices in hemodialysis patients receiv-
had limited clinical utility.ing epoetin.
Conclusions. Iron deficiency commonly develops duringBackground. Iron deficiency remains a common cause of
epoetin therapy, and parenteral iron administration may resulthyporesponsiveness to epoetin in hemodialysis patients. How-
in a clinically significant reduction in epoetin dose. The useever, considerable controversy exists regarding the best strate-
of transferrin saturation or serum ferritin as an indicator forgies for diagnosis and treatment.
parenteral iron administration has limited utility.Methods. As part of a multicenter randomized clinical trial
of intravenous versus subcutaneous administration of epoetin,
we made monthly determinations of serum iron, total iron
binding capacity, percentage transferrin saturation, and serum The availability of recombinant human erythropoietinferritin. If a patient had serum ferritin 100 ng/mL or the
(epoetin) has markedly altered the treatment of the ane-combination of serum ferritin 400 ng/mL and a transferrin
mia of chronic renal failure and greatly reduced the needsaturation 20%, he/she received parenteral iron, given as
iron dextran 100 mg at ten consecutive dialysis sessions. We for transfusions in these patients. A number of clinical
analyzed parenteral iron use during the trial, the effect of its circumstances may lead to decreased responsiveness to
administration on iron indices and epoetin dose, and the ability epoetin, the most important of which is iron deficiency.of the iron indices to predict a reduction in epoetin dose in
Considerable emphasis has been placed on the recognitionresponse to parenteral iron administration.
and treatment of iron deficiency in epoetin-treated chronicResults. Eighty-seven percent of the 208 patients required
parenteral iron to maintain adequate iron stores at an average renal failure patients, yet controversy exists regarding the
dose of 1516 mg over 41.7 weeks, or 36 mg/week. Only two of best strategies for diagnosis and management [1]. Several
180 patients experienced serious reactions to intravenous iron investigators have suggested that serum ferritin is the mostadministration. Two thirds of the patients receiving parenteral
useful marker of iron deficiency in an otherwise normaliron had a decrease in their epoetin requirement of at least 30
population [2]. However, serum ferritin is elevated inU/kg/week compared with 29% of patients who did not receive
iron (P  0.004). The average dose decrease 12 weeks after chronic renal failure and inflammatory states, and the
initiating iron therapy was 1763 U/week. A serum ferritin200 usual thresholds for the diagnosis of iron deficiency may
ng/mL had the best positive predictive value (76%) for pre- not be applicable under these circumstances [3]. The
other readily obtainable marker of iron deficiency, serum
1 Investigators, support personnel and centers are listed in the Ap- transferrin saturation, may also have decreased reliabil-
pendix. ity in patients with chronic renal failure [4]. Several other
diagnostic tests, including serum transferrin receptors,Key words: anemia, parenteral iron, serum ferritin, transferrin satura-
tion, recombinant human erythropoietin. red blood cell protoporphyrins, percentage of hypochro-
mic red cells, and reticulocyte hemoglobin concentration,Received for publication June 5, 2000
have demonstrated some utility, but require specializedand in revised form December 26, 2000
Accepted for publication January 25, 2001 equipment and are not widely available [1].
We have recently completed a study comparing intra- 2001 by the International Society of Nephrology
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Table 1. Clinical characteristics of patientsvenous to subcutaneous epoetin administration in hemo-
dialysis patients [5]. As part of the protocol, we obtained N 208
Age years 60.212.9monthly serum irons, total iron binding concentrations,
Male % 98.6and serum ferritins and used a specific algorithm for Diabetic % 42.8
parenteral iron administration. Using this database, we Length of dialysis hours 3.800.36
Years on dialysis 3.703.93have analyzed the diagnostic accuracy of the commonly
Years on epoetin 2.171.51used iron parameters and the influence of parenteral Serum albumin g/dL 3.80.4
iron administration on epoetin requirements. Serum aluminum lg/L 21.816.9
Serum iron lg/dL 70.141.7
Total iron binding capacity lg/dL 238.267.3
Transferrin saturation % 28.310.7METHODS
Serum ferritin ng/mL 301223
As part of a multicenter, randomized clinical trial of
intravenous versus subcutaneous administration of epoe-
tin (Epogen; Amgen, Thousand Oaks, CA, USA), we week in the subsequent 12 weeks while maintaining the
have collected monthly data on serum iron parameters, target hematocrit of 30 to 33%. This definition was based
including serum iron, total iron binding capacity (TIBC), on the epoetin dosing algorithm for the main study,
percentage transferrin saturation (TS%), and serum fer- which required weekly hematocrits, and if the hematocrit
ritin. The main study was designed to compare the intra- was outside the target range for two consecutive weeks
venous to subcutaneous administration of epoetin in terms during the maintenance period, the epoetin dose was
of the average weekly dose required to maintain a target altered by 30 U/kg/week. Therefore, a decrease in epoe-
hematocrit of 30 to 33% for 26 weeks. The study was a tin dose reflected an increase in hematocrit to 33% in
parallel group design, and after randomization, patients the previous two weeks. This definition allowed us to
underwent dose reductions until their hematocrits were examine the value of serum ferritin and transferrin satu-
less than 30% for two consecutive weeks. Then doses ration determinations in predicting the hematologic re-
were gradually increased until the hematocrits were once sponse to parenteral iron administration.
again greater than 30%. The hematocrit was then main-
Statistical methodstained in the target range of 30 to 33% for 26 weeks
using a specific dosing algorithm. The design and results Changes in iron indices following parenteral iron were
of the main study have previously been reported [5]. analyzed using the one sample t test. The percentage of
The management of oral and parenteral iron adminis- patients having a reduction in their epoetin dose of at
tration was as follows during the study. Patients entering least 30 U/kg/week following a course of parenteral iron
the study were required to have a transferrin saturation compared with those receiving no iron was analyzed using
20% and a serum ferritin 100 ng/mL. Patients were Fisher’s exact test. This analysis was repeated using a de-
prescribed oral iron, Niferex-150 (Central Pharmaceu- crease of 60 U/kg/week as the threshold for response. All
ticals, Inc./Schwarz Pharma, Inc., Mequon, WI, USA) statistical tests were two-sided, and P  0.05 was consid-
one capsule twice daily, but oral iron therapy was not ered statistically significant. SAS (version 6) was used
specifically monitored. To avoid prolonged periods of iron for all analyses [6]. Results are reported as means  SD.
deficiency and to minimize epoetin doses, we required
frequent measurements of iron status and prescribed
RESULTSliberal parenteral iron replacement. Monthly midweek,
Iron usepredialysis determinations of serum iron, TIBC, and se-
rum ferritin were obtained. If a patient had a serum The clinical characteristics of the patients at entry into
ferritin 100 ng/mL or the combination of a serum fer- the study are summarized in Table 1. Two hundred eight
ritin 400 ng/mL and a transferrin saturation 20%, patients were randomized to receive either the subcuta-
he/she received parenteral iron. The parenteral iron was neous (N  107) or intravenous (N  101) route of
given as iron dextran (INFeD; Schein Pharmaceutical, epoetin administration. Although all the patients were
Inc., Florham Park, NJ, USA) 100 mg at ten consecutive prescribed oral iron, parenteral iron was required at
dialysis sessions. some time during the study by 180 (87%) patients to
For our post hoc analysis, because there is no generally maintain iron parameters within our specific target
accepted absolute standard for the diagnosis of iron de- range. Thirty-one percent of the randomized patients
ficiency, particularly in epoetin-treated patients, we de- required a single course. Twenty-four percent required
veloped a functional definition. Patients were defined two courses, and 32% required three courses of ten 100
as having functional iron deficiency if, after receiving a mg doses of parenteral iron. The average total amount
course of parenteral iron, they were able to have a reduc- of intravenous iron administered per patient was 1516 
1173 mg. The average time in the study was 41.7  17.3tion in their weekly epoetin dose of at least 30 U/kg/
Kaufman et al: Iron indices in patients on epoetin302
Fig. 1. Values for transferrin saturation in
the three months prior to the first value20%.
Values in bars are means, and error bars are
standard deviations. P  0.001, comparing
current month to all prior months.
week. The 180 patients receiving parenteral iron received tion20% and serum ferritin400 ng/mL had an MCV
below the lower limit of normal (80 fL).a total of 3588 doses of iron dextran. Only two of these
We examined the rate of change in the commonly180 patients (1.1%) had serious adverse reactions that
used diagnostic indices. Figure 1 summarizes the valuesprecluded subsequent administration of parenteral iron
for transferrin saturation in the three months prior todextran. Both patients experienced hypotensive episodes
the first value 20%. In this analysis, patients who hadshortly after the iron infusion was completed. Because
received any parenteral iron in the eight weeks prior tothe patients were on hemodialysis at the time, it is possi-
the transferrin saturation value of20% were excluded.ble that the events were unrelated to the iron dextran.
Similarly, Figure 2 summarizes the values for serum ferri-However, the patients’ physicians did not feel it was safe
tin in the three months prior to the first value200 ng/mL.to rechallenge the patients. Since we did not specifically
The values for transferrin saturation and serum ferritinrequire reporting of minor reactions, we cannot com-
changed rapidly, with the largest changes occurring inment on their frequency.
the month just prior to the abnormal value. The changes
Diagnostic studies in iron parameters in response to parenteral iron are
summarized in Table 2. Only patients who had repeatA transferrin saturation 20% has been advocated as
determinations of iron parameters at least one montha diagnostic threshold for iron deficiency [7]. Seventy-
after the completion of a ten-dose course of parenteralnine percent of patients had a transferrin saturation
iron are included in this analysis. Data were available20% at some time during the study. Most of the mea-
on 136 of the 180 patients receiving parenteral iron,surements of transferrin saturation occurred with a con-
although three of these did not have follow-up serumcomitant low serum ferritin concentration indicative of
ferritin values. Serum ferritin, TIBC, and transferrin sat-iron deficiency, but 21% occurred with a serum ferritin
uration, but not serum iron, changed significantly within
400 ng/mL. Twelve percent of the low transferrin satu- a month of administration of parenteral iron. Table 3
rations occurred with a serum ferritin 100 ng/mL. shows the values for transferrin saturation and serum
Thirty-four percent had a value of 100 to 199 ng/mL. ferritin just prior to starting parenteral iron and their
Twenty-one percent were 200 to 299 ng/mL, and 10% effects on the response of these parameters to parenteral
were 300 to 399 ng/mL. A serum ferritin 100 ng/mL, iron. If patients were stratified by their serum ferritin
a value frequently cited as diagnostic of iron deficiency values prior to starting iron, those with serum ferritins
in patients with chronic renal failure [7], was noted in greater than 300 ng/mL did not have a significant increase
36% of patients at some time during the study. In the in their transferrin saturation or serum ferritin in re-
majority of patients (73%) with a serum ferritin 100 sponse to parenteral iron, although the apparent lack of
ng/mL, the simultaneously measured value for trans- response may be due to the small sample size.
ferrin saturation was20%, including 31% with a trans-
Hematologic response to parenteral iron and accuracyferrin saturation 28%. In this study, mean corpuscular
of diagnostic studiesvolume (MCV) was an insensitive index of iron defi-
ciency. Only 5% of the patients with a serum ferritin During the maintenance phase of our study, epoetin
doses were adjusted to maintain a target hematocrit of100 ng/mL or the combination of a transferrin satura-
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Fig. 2. Values for serum ferritin in the three
months prior to the first value 200 ng/mL.
Values in bars are means and error bars are
standard deviations. P  0.001, comparing
current month to all prior months.
Table 2. Effect of parenteral iron on iron indices deficiency if after receiving a course of parenteral iron,
they were able to have a reduction in their weekly epoe-Value at least
Value just one month tin dose of at least 30 U/kg/week in the subsequent 12
prior to after completing weeks, while maintaining the target hematocrit of 30 toinitiating course of
33%. A dose change of 30 U/kg/week was the minimalLaboratory measurement parenteral iron parenteral iron P value
change allowed by this dosing algorithm and correspondedSerum iron lg/dL
(N  136) 54.940.1 57.928.5 0.43 to 32% of the average dose (95 U/kg/week) in the group
Total iron binding capacity receiving epoetin subcutaneously and 21% of the aver-
lg/dL (N  136) 24868 22964 0.001
age dose (140 U/kg/week) in the group receiving epoetinTransferrin saturation %
(N  136) 22.412.6 25.911.6 0.008 intravenously. Forty of 60 (67%) of those patients receiv-
Serum ferritin ng/mL ing parenteral iron during the maintenance phase of the
(N  133) 200147 319185 0.001
study had a decrease in their epoetin dose, while only 6
of 21 (29%) patients not receiving parenteral iron had
a similar decrease (P  0.004 by Fisher’s exact test). If
a more restrictive definition of a response to parenteral30 to 33%. Therefore, the expected response of iron-
iron as a change in dose of at least 60 U/kg/week wasdeficient patients receiving parenteral iron during this
used, 24 of 60 (40%) patients receiving parenteral ironphase would be a decrease in the epoetin dose necessary
responded. Only 2 of 21 (10%) patients not receivingto maintain the target hematocrit. Figure 3 summarizes
parenteral iron had a spontaneous change in their epoe-the changes in average weekly epoetin dose following a
tin dose of this magnitude (P  0.01).course of parenteral iron. The weekly dose began to fall
Using this functional definition of iron deficiency, wein the fourth week after beginning iron administration,
have examined the diagnostic accuracy of different thresh-continued to fall over the next several weeks, and
olds for serum ferritin and transferrin saturation in pre-reached the maximum decrease by the 12th week after
dicting the response to parenteral iron (Table 4). Thethe initiation of therapy. At week 12, the mean decrease
conventional tests of diagnostic accuracy, sensitivity, andin epoetin dose was 1763  3841 U/week.
specificity could not be used since parenteral iron wasTo determine the diagnostic accuracy of our iron pa-
administered to a selected group of study patients, thoserameters, we examined the ability of different values
with a serum ferritin 100 ng/mL or the combination ofto predict a response to parenteral iron administration.
a transferrin saturation20% and a serum ferritin400Using the data from patients who received parenteral
ng/mL. Table 4 lists the number of true positives, patientsiron during the maintenance phase of our study, we have
whose iron parameters fell below the threshold valuedeveloped a functional definition of iron deficiency. Only
and who had reduction in epoetin dose after parenteralpatients receiving parenteral iron during the 26-week
iron administration, and true negatives, patients whosemaintenance phase of the study were included in this
iron parameters exceeded a threshold value and who didanalysis, since it was the only phase of the study in which
not have a reduction in epoetin dose after parenteralhematocrit was maintained in the target range of 30 to
33%. Patients were defined as having functional iron iron administration. We also calculated the positive pre-
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Table 3. Effect of parenteral iron on iron parameters stratified by baseline values
Transferrin saturation Serum ferritin
One One
Prior to month Prior to month
N iron after iron Change P iron after iron Change P
Serum ferritin
100 ng/mL 47 27.311.8 29.79.7 2.415.3 0.28 7817 21687 13890 0.001
100–199 ng/mL 35 19.710.1 25.011.1 5.310.1 0.004 15329 297155 143152 0.001
200–299 ng/mL 28 22.317.6 25.315.5 3.022.6 0.50 24429 364165 120155 0.001
300–399 ng/mL 14 17.24.7 20.87.4 3.69.1 0.16 34928 409164 59173 0.22
400 ng/mL 10 19.77.6 19.27.2 0.58.8 0.88 589130 615286 26335 0.81
Transferrin saturation
20% 77 15.34.0 23.211.2 7.911.7 0.001 233135 356177 124167 0.001
20% 59 31.614.0 29.511.4 2.117.4 0.35 157153 270185 113152 0.001
Fig. 3. Changes in epoetin dose after begin-
ning iron therapy.
dictive value, the proportion of patients with a value for DISCUSSION
the iron parameter below the threshold value who had In the absence of iron replacement, the development
a reduction in epoetin dose after parenteral administra- of iron deficiency during epoetin therapy is common [8],
tion, and the negative predictive value, the proportion and several authors have shown that oral iron is often
inadequate to maintain iron stores [9, 10]. In our study,of patients with a value for the iron parameter exceeding
although all patients received oral iron, 87% requiredthe threshold value who did not have a reduction in
parenteral iron at some time during the study to repleteepoetin dose after parenteral iron administration. Because
their iron stores. The average total dose of iron receivedparenteral iron was not administered to patients with
per patient was 1516  1173 mg over an average timeserum ferritins400 ng/mL, no negative predictive value
of 41.7 17.3 weeks, or approximately 36 mg/week. Thecan be calculated for this value. We summarized the
National Kidney Foundation has recommended adminis-parameters for the two different definitions of functional
tering 25 to 100 mg of parenteral iron weekly as mainte-
iron deficiency, either a change in dose of30 U/kg/week nance iron therapy [7]. The actual requirements in our
or60 U/kg/week. No iron parameter had a positive and patient population fall at the lower end of this recom-
negative predictive value exceeding 0.80, a commonly mendation.
used cutoff for diagnostic utility. A serum ferritin value The administration of parenteral iron in the doses
200 had the best diagnostic utility with the highest utilized in our study (1000 mg over 10 dialysis sessions)
combined positive and negative predictive value at both results in a rapid response in terms of epoetin dose and
iron indices. Epoetin doses begin decreasing within fourdefinitions of functional iron deficiency.
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Table 4. Diagnostic accuracy of serum ferritin and transferrin saturation in predicting response to parenteral iron
Epoetin dose change of 30 U/kg/week Epoetin dose change of 60 U/kg/week
Positive Negative Positive Negative
True True predictive predictive True True predictive predictive
positives negatives value value positives negatives value value
Serum ferritin threshold
100 ng/mL 13 16 0.76 0.37 10 30 0.63 0.37
200 ng/mL 29 11 0.76 0.50 19 19 0.53 0.79
300 ng/mL 37 3 0.68 0.50 22 5 0.42 0.714
400 ng/mL 40 0 0.67 NA 24 0 0.40 NA
Transferrin saturation threshold %
12 2 17 0.40 0.31 2 33 0.40 0.60
16 6 13 0.46 0.28 5 28 0.39 0.60
20 24 6 0.63 0.28 14 12 0.37 0.55
24 29 4 0.64 0.27 18 9 0.40 0.60
28 37 4 0.70 0.57 20 8 0.42 0.67
NA is not applicable.
weeks of initiating parenteral iron therapy and continue 573 hemodialysis patients and found a similar low inci-
dence of adverse events, with 27 patients (4.7%) havingto fall for the subsequent eight weeks. The average de-
crease in dose of 1763 U/week in response to parenteral adverse reactions [12]. Four (0.7%) had serious reac-
tions, including one cardiac arrest and three hospitaliza-iron administration is 20% of the average maintenance
epoetin dose of 8694 U/week [5], indicating that paren- tions, but no deaths. Ten patients (1.7%) had anaphylac-
toid reactions including the four serious reactions.teral iron administration results in a clinically significant
reduction in epoetin dose. Values for serum iron, total Hypotension occurred in 0.5%.
Although the importance of iron deficiency as a causeiron binding capacity, transferrin saturation, and serum
ferritin reach a new baseline within one month of iron of epoetin hyporesponsiveness in hemodialysis patients
is well recognized, considerable controversy surroundsadministration. Lynn, Mitchell, and Shepperd examined
the rate of change in serum ferritin after 1 g of parenteral its diagnosis. The “gold standard” for diagnosis in the
nonuremic population has been low or absent iron stain-iron therapy administered to 15 patients on hemodialysis
not receiving epoetin [11]. At one to two months, the ing on bone marrow aspirates. Several studies have com-
pared the standard serum iron parameters of transferrinaverage rise in serum ferritin was 228 ng/mL (range 163
to 364) for each gram of iron administered intravenously. saturation and serum ferritin to iron staining of bone
marrow samples in hemodialysis patients not receivingOur patients had an average increase in serum ferritin
of 152 ng/mL one month after administering 1 g of paren- epoetin. Most of these studies indicate that serum ferritin
correlates well with bone marrow iron staining. Valuesteral iron.
We noted that serum ferritin and transferrin saturation of serum ferritin from 35 to 300 ng/mL may be indicative
of iron deficiency, while serum ferritins 300 ng/mLdecreased rapidly prior to iron administration in those
patients meeting our criteria for parenteral iron adminis- indicate adequate bone marrow iron content [13–17].
However, Ali et al found that serum ferritin did nottration. In the month prior to the first laboratory determi-
nation with a transferrin saturation20%, the value was correlate with bone marrow iron stores in 36 hemodialy-
sis patients [3]. In their study, performed before the27.6  8.5%, decreasing to 16.0  3.3% in the following
month. Similarly, in patients with serum ferritins 200 availability of epoetin, serum ferritin was increased in ten
marrow-iron-depleted subjects. The subjective nature ofng/mL, the values decreased from 286  101 to 153 
37 ng/mL within one month. These findings suggest that the assessment of bone marrow iron content has been
highlighted by some authors, who argue that the absencepatients may have transferrin saturation and serum ferri-
tin values that are considered quite adequate and within of visible stainable bone marrow iron cannot be equated
with depleted iron stores [18]. Furthermore, there areone month develop values diagnostic of iron deficiency.
If routine determinations of iron diagnostic indices are no studies correlating bone marrow iron staining with
the response to parenteral iron in patients with chronicdone quarterly, as is common practice, patients may have
unrecognized iron deficiency for several months. renal failure.
Several investigators have correlated the hemoglobinThe use of parenteral iron in our study was relatively
free of adverse events, with only two serious reactions, response to parenteral iron administration with iron pa-
rameters prior to administration in patients not receivingboth hypotensive episodes, out of 3588 (0.04%) doses
of iron and 180 (1.1%) patients. Fishbane et al retrospec- epoetin. Allegra, Mengozzi, and Vasile found that in 72
hemodialysis patients, no patient with a serum ferritintively reviewed the safety of intravenous iron dextran in
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191 ng/mL responded to iron with an increase in hemo- iron deficiency were a serum ferritin150 ng/mL (sensi-
tivity of 71% and a specificity of 69%) or a transferringlobin, while eight of 27 patients with a serum ferritin
of 19 to 191 ng/mL and 14 of 30 with a serum ferritin19 saturation 21% (sensitivity of 81% and specificity of
63%) [4]. These cutoff values are similar to our findingng/mL responded [19]. Lynn, Mitchell, and Shepperd
examined the response to 1 g of parenteral iron in 31 that a serum ferritin of 200 ng/mL had the best com-
bined positive and negative predictive value, but withhemodialysis patients [11]. No patient with a serum ferri-
tin55 ng/mL had an increase in hemoglobin concentra- limited clinical utility. We were unable to demonstrate
clinically useful predictive utility for any cutoff valuestion of 1 g/dL, while 17 of 21 patients with a serum
ferritin 55 ng/mL had an increase in hemoglobin con- for transferrin saturation.
We used a parenteral iron algorithm that standardizedcentration of1 g/dL. This difference was highly signifi-
cant (P  0.001). Beallo et al found that a serum ferritin the administration of iron in response to abnormal iron
indices. Several authors have suggested that intravenous35 ng/mL not only correlated with absent bone marrow
iron stores, but also predicted a positive response to iron should be given on a maintenance schedule in hemo-
dialysis patients, with regular weekly, biweekly, orparenteral iron [20].
The studies cited previously in this article were per- monthly doses [23, 24]. In studies comparing these regi-
mens to oral iron, lower doses of epoetin for similar orformed in patients not receiving epoetin. It has been
suggested that the iron levels needed for adequate eryth- high hematocrits were necessary in patients receiving
maintenance intravenous iron. However, no studies areropoiesis in hemodialysis patients may be increased un-
der exogenous epoetin stimulation [1]. Patients may have available comparing this regimen with regimens similar
to ours, where parenteral iron is given in response toadequate iron stores, but diminished responsiveness to
epoetin administration that can be enhanced by paren- abnormal iron indices. In our study, the average reduc-
tion in epoetin dose 12 weeks following parenteral ironteral iron administration. We have examined this phe-
nomenon by developing a functional definition of iron therapy was 1763 3841 U/week. It is possible that with
maintenance iron therapy periods of iron deficiency candeficiency based on the response of our patients to paren-
teral iron administration. If patients responded to intra- be avoided, allowing for sustained reductions in epoetin
dose. Our finding that iron parameters may decreasevenous iron dextran with a subsequent fall in their epoe-
tin requirements (30 U/kg/week) while maintaining a markedly over a period of a month also suggest an advan-
tage for regular maintenance iron therapy, rather thanstable hematocrit, they were defined as being function-
ally iron deficient. In the 26-week maintenance phase of administering it in response to abnormal ferritins or
transferrin saturations.our study, during which epoetin doses were carefully
adjusted to maintain our target hematocrit of 30 to 33%, It should be recognized that the major benefit of par-
enteral iron administration in hemodialysis patients re-60 patients received parenteral iron. Sixty-seven percent
had a decrease in their epoetin dose of 30 U/kg/week ceiving epoetin is the lowering of the epoetin dose. As
indicated by our results, although the average dose re-in the subsequent weeks. In contrast, only 29% not re-
ceiving parenteral iron had a similar spontaneous de- duction is clinically significant, 1763 U/week or approxi-
mately 20% of the average weekly dose, a significantcrease in their epoetin dose.
Fishbane et al have also used the response to paren- number of patients do not respond to iron administration
with an increased hematopoietic response. Only 66% ofteral iron to define iron deficiency in patients receiving
epoetin [4]. Forty-seven patients with serum ferritin lev- patients had a dose reduction 30 U/kg/week, and only
40% had a reduction of 60 /kg/week. It would beels 600 ng/mL were treated with intravenous iron dex-
tran, 1000 mg over 10 dialysis sessions. The target hema- useful to have cutoff values of transferrin saturation or
ferritin that would predict a positive response to iron,tocrit range was 30 to 34%. The patients were followed
for two months and those whose hematocrit values in- but we and others have not been able to define clinically
useful cutoff values [4]. Using our iron dosing algorithm,creased by 5% or who had a 10% decrease in their
epoetin dose were classified as having iron deficiency. we administered parenteral iron to 87% of our study
population and noted a clinically important epoetin doseIn results similar to those in the current report, they
found that 31 (66%) of these patients responded to par- reduction in 40 to 66% of patients. Whether it is clinically
desirable to administer parenteral iron to a significantenteral iron.
They have also examined the utility of iron indices in minority of patients who may not benefit with a reduction
in epoetin dose depends on the risks and economic costspredicting the responses to parenteral iron in patients
receiving epoetin [4, 21, 22]. When these authors exam- of parenteral iron administration. The risk of a severe
acute reaction to parenteral iron dextran has been re-ined the predictive value of specific serum ferritin and
transferrin saturation thresholds, they found that the ported to be 0.7%, although it is probably lower with
newer parenteral iron preparations [12, 25]. Several long-receiver operating curves demonstrated that none of the
indices had a high level of utility (sensitivity and specific- term risks associated with iron administration have been
proposed, including tissue iron accumulation, increasedity 80%). The best cutoff values for the diagnosis of
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Regarding economic costs, these have not been rigor- APPENDIX
ously assessed. Recently, Besarab et al have published
The Department of Veterans Affairs Cooperative Study group in-a study comparing two protocols for maintenance iron
cludes the following participating investigators, support staff and cen-
infusions and demonstrated that from a dialysis facilities ters (*former participant).
Office of the Chairman: J.S. Kaufman (chairman), R.A. Cxypoliskiperspective, targeting a transferrin saturation of 30 to
(clinic coordinator), P. London (secretary) (Boston, MA, USA).50% versus 20 to 30% was cost effective even though it
Participating investigators and support personnel (Veterans Affairs
required an increase in monthly maintenance parenteral Medical Centers): E. Young and P. Rose (Ann Arbor, MI); G. Schmitt,
K. Bold, J. Briggs, and V. Lee* (Boston, MA); D. Kaji, F.M. Ohsumi*,iron administration from 176 to 501 mg/month [26]. It
and H. Chen (Bronx, NY); M.B. Ganz, S. Nurko, and D.G. Linnseems likely that given the poor predictive value of the
(Cleveland, OH); R.E. Cronin, and V.N. Kemp (Dallas, TX); M.G.
readily available iron parameters, in order to effect an Saklayen, S. Adams, Y.J. Jenkins, and M. Davis* (Dayton, OH); S.
Sastrasinh and K.A. Lordi (East Orange, NJ); Z. Nawab and B. Kepka*overall epoetin dose reduction in the hemodialysis popu-
(Hines, IL); G. Dolson, R. Therappel, and A. Bonner* (Houston, TX);lation, parenteral iron will need to be administered to a Hasbargen, S.C. Nielsen, and A. Frame (Indianapolis, IN); G. Shah
significant percentage of patients who will not respond and D. Lim (Long Beach, CA); C.A. Vaamonde, L. Cason, J.
Edelstein*, and C. Serrano* (Miami, FL); J.G. Kleinman, J. Schramm,with an epoetin dose reduction. What the appropriate
E. Sheahan-Meyer*, and B.J. Jackson* (Milwaukee, WI); V. Batumanupper limit of serum ferritin should be to minimize the and D.M. Archie (New Orleans, LA); D.S. Goldfarb and R. Discipulo
potential long-term consequences of parenteral iron ad- (New York, NY); T.E. Dixon and E. Lamonica (Northport, NY); J.A.
Pederson and T. Albert (Oklahoma City, OK); R.L. Jamison and D.L.ministration remains to be determined.
Usi (Palo Alto, CA); P.M. Palevsky and P. Baltz Salai (Pittsburgh,Our study shows that the majority of patients receiving PA); S. Anderson, M. Wolfson*, and M. Cummings-Cosgrove (Port-
epoetin and prescribed the usual doses of oral iron re- land, OR); G. Feldman, M.S. Katz*, and J.A. Burns (Richmond, VA);
S.C. Thomson and M.V. Meek (San Diego, CA); C. Rosado, E. Gali-quire parenteral iron to maintain adequate iron stores.
ndo*, P. Carde*, and J. Bou* (San Juan, Puerto Rico); U.F. MichaelChanges in iron indices develop rapidly with marked and L.F. Kirlin (Tucson, AZ).
decreases occurring over a period of one month. There- Executive Committee: J.S. Kaufman (chairman; Boston, MA); C.L.
Fye (pharmacist; Albuquerque, NM); D.S. Goldfarb (nephrologist;fore, providing parenteral iron in response to abnormal
New York, NY); W.G. Henderson [Chief, Hines Cooperative Studiesquarterly determinations of iron indices, as is commonly Program Coordinating Center (CSPCC)] and D.J. Reda (study biostati-
done, may leave patients iron deficient for prolonged stician; Hines, IL); J.G. Kleinman (nephrologist; Milwaukee, WI); and
C.A. Vaamonde (nephrologist; Miami, FL).periods. Acute adverse reactions to the administration of
Biostatistics and Research Data Processing at Hines CSPCC: D.J.
iron dextran were infrequent, with only 2 of 180 patients Reda (study biostatistician and assistant chief), W.G. Henderson
(chief), D. Semlow (assistant chief for operations), L. Anfinsen (pro-experiencing serious reactions. Parenteral iron adminis-
grammer), and B. Mackay.tration according to our protocol reduces epoetin re-
Albuquerque CSP Pharmacy Coordinating Center: C.L. Fye (phar-
quirements. Two thirds of the patients had a reduction macist), M.R. Sather (chief), F.R. Chacon, M. Drago, and W.H. Gagne.
Data Monitoring Board: T.I. Steinman (chairman; Harvard Medicalin their epoetin requirement of at least 30 U/kg/week.
School, Boston, MA); A. Nissenson (UCLA School of Medicine, LosThe average dose decrease 12 weeks after initiating par-
Angeles, CA); R.D. Swartz (University of Michigan School of Medicine,
enteral iron was 1763 U/week. Analyzing the ability of Ann Arbor, MI ); M. Symons (University of North Carolina School of
Public Health, Chapel Hill, NC).serum ferritin or transferrin saturation to predict a posi-
Cooperative Studies Program Administration: J. Feussner (Chieftive response to parenteral iron indicated that neither
Research and Development Officer), S. Berkowitz (staff assistant),
of these indices had combined positive and negative pre- and P. Huang (staff assistant; Department of Veterans Affairs Head-
quarters, Washington, D.C.); D. Deykin (ex-chief, Cooperative Studiesdictive values 0.80. A serum ferritin 200 ng/mL was
Program), and J. Gold (administrative officer; Boston, MA).the best value for predicting a response to parenteral
iron, but had limited clinical utility.
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